ABBV vs INSM

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Insmed Incorporated exhibits a weak deterministic health profile with a Piotroski F-Score of 3/9, indicating significant fundamental instability. While the company shows explosive revenue growth of 152.6%, this is offset by extreme valuation metrics (Price/Sales of 55.10) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The stark disconnect between the 'Strong Buy' analyst consensus and the bearish insider activity—including significant sales by the CEO and COO—suggests a high-risk speculative profile rather than a value-driven investment.